Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

PURPOSE: This randomized, multicenter, open-label, phase Ib/II study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer or gastroesophageal junction (GEJ) cancer. PATIENTS AND METHODS: Second-line patients were randomized 2:2:1 to receive...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Kelly, Ronan J., Lee, Jeeyun, Bang, Yung-Jue, Almhanna, Khaldoun, Blum-Murphy, Mariela, Catenacci, Daniel V.T., Chung, Hyun Cheol, Wainberg, Zev A., Gibson, Michael K., Lee, Keun-Wook, Bendell, Johanna C., Denlinger, Crystal S., Chee, Cheng Ean, Omori, Takeshi, Leidner, Rom, Lenz, Heinz-Josef, Chao, Yee, Rebelatto, Marlon C., Brohawn, Philip Z., He, Peng, McDevitt, Jennifer, Sheth, Siddharth, Englert, Judson M., Ku, Geoffrey Y.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7748730/
https://ncbi.nlm.nih.gov/pubmed/31676670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-2443
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi